• Je něco špatně v tomto záznamu ?

How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy

M. Šimek, K. Nešporová, A. Kocurková, T. Foglová, G. Ambrožová, V. Velebný, L. Kubala, M. Hermannová

. 2021 ; 263 (-) : 117927. [pub] 20210317

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025429

There is inconsistent information regarding the size effects of exogenously given hyaluronan on its in vivo fate. The data are often biased by the poor quality of hyaluronan and non-ideal labelling strategies used for resolving exogenous/endogenous hyaluronan, which only monitor the label and not hyaluronan itself. To overcome these drawbacks and establish the pharmacokinetics of intravenous hyaluronan in relation to its Mw, 13C-labelled HA of five Mws from 13.6-1562 kDa was prepared and administered to mice at doses 25-50 mg kg-1. The elimination efficiency increased with decreasing Mw. Low Mw hyaluronan was rapidly eliminated as small hyaluronan fragments in urine, while high Mw hyaluronan exhibited saturable kinetics and complete metabolization within 48 h. All tested Mws exhibited a similar uptake by liver cells and metabolization into activated sugars. 13C-labelling combined with LC-MS provides an excellent approach to elucidating in vivo fate and biological activities of hyaluronan.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025429
003      
CZ-PrNML
005      
20211026133826.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.carbpol.2021.117927 $2 doi
035    __
$a (PubMed)33858586
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Šimek, Matěj $u Contipro a.s., Dolní Dobrouč 401, 56102, Dolní Dobrouč, Czech Republic; Department of Analytical Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic
245    10
$a How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy / $c M. Šimek, K. Nešporová, A. Kocurková, T. Foglová, G. Ambrožová, V. Velebný, L. Kubala, M. Hermannová
520    9_
$a There is inconsistent information regarding the size effects of exogenously given hyaluronan on its in vivo fate. The data are often biased by the poor quality of hyaluronan and non-ideal labelling strategies used for resolving exogenous/endogenous hyaluronan, which only monitor the label and not hyaluronan itself. To overcome these drawbacks and establish the pharmacokinetics of intravenous hyaluronan in relation to its Mw, 13C-labelled HA of five Mws from 13.6-1562 kDa was prepared and administered to mice at doses 25-50 mg kg-1. The elimination efficiency increased with decreasing Mw. Low Mw hyaluronan was rapidly eliminated as small hyaluronan fragments in urine, while high Mw hyaluronan exhibited saturable kinetics and complete metabolization within 48 h. All tested Mws exhibited a similar uptake by liver cells and metabolization into activated sugars. 13C-labelling combined with LC-MS provides an excellent approach to elucidating in vivo fate and biological activities of hyaluronan.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a zvířata $7 D000818
650    _2
$a kosti a kostní tkáň $x metabolismus $7 D001842
650    _2
$a izotopy uhlíku $x chemie $x metabolismus $x farmakokinetika $7 D002247
650    _2
$a chrupavka $x metabolismus $7 D002356
650    _2
$a cyklická ADP-ribosa $x metabolismus $7 D036563
650    _2
$a cesty eliminace léčiva $7 D000084342
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kyselina hyaluronová $x chemie $x metabolismus $x farmakokinetika $7 D006820
650    _2
$a izotopové značení $x metody $7 D007553
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a molekulová hmotnost $7 D008970
650    _2
$a tkáňová distribuce $7 D014018
650    _2
$a uridindifosfátglukosa $x metabolismus $7 D014532
650    _2
$a uridindifosfát-N-acetylglukosamin $x metabolismus $7 D014537
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nešporová, Kristina $u Contipro a.s., Dolní Dobrouč 401, 56102, Dolní Dobrouč, Czech Republic
700    1_
$a Kocurková, Anna $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic; Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic; Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Foglová, Tereza $u Contipro a.s., Dolní Dobrouč 401, 56102, Dolní Dobrouč, Czech Republic
700    1_
$a Ambrožová, Gabriela $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic; Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic
700    1_
$a Velebný, Vladimír $u Contipro a.s., Dolní Dobrouč 401, 56102, Dolní Dobrouč, Czech Republic
700    1_
$a Kubala, Lukáš $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic; Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic; Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Electronic address: kubalal@ibp.cz
700    1_
$a Hermannová, Martina $u Contipro a.s., Dolní Dobrouč 401, 56102, Dolní Dobrouč, Czech Republic. Electronic address: martina.hermannova@contipro.com
773    0_
$w MED00006149 $t Carbohydrate polymers $x 1879-1344 $g Roč. 263, č. - (2021), s. 117927
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33858586 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133831 $b ABA008
999    __
$a ok $b bmc $g 1714466 $s 1145936
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 263 $c - $d 117927 $e 20210317 $i 1879-1344 $m Carbohydrate polymers $n Carbohydr Polym $x MED00006149
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace